This report was first published by Endpoints News. To see the original version, click here
An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the technology — putting it on track for a potential FDA approval in the first half of next year.
The therapy, made by Intellia Therapeutics, uses the molecular scissors of CRISPR to break a gene that contributes to disfiguring and dangerous swelling attacks in people with hereditary angioedema. The one-time infusion reduced those attacks by 87% compared to placebo, the company announced Monday morning.
您已阅读12%（629字），剩余88%（4681字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。